Attached files
file | filename |
---|---|
EX-32.2 - EX-32.2 - STEMLINE THERAPEUTICS INC | a17-1159_1ex32d2.htm |
EX-32.1 - EX-32.1 - STEMLINE THERAPEUTICS INC | a17-1159_1ex32d1.htm |
EX-31.2 - EX-31.2 - STEMLINE THERAPEUTICS INC | a17-1159_1ex31d2.htm |
EX-31.1 - EX-31.1 - STEMLINE THERAPEUTICS INC | a17-1159_1ex31d1.htm |
EX-21.1 - EX-21.1 - STEMLINE THERAPEUTICS INC | a17-1159_1ex21d1.htm |
10-K - 10-K - STEMLINE THERAPEUTICS INC | a17-1159_110k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-8 No. 333-188115) pertaining to Stemline Therapeutics, Inc. 2012 Equity Incentive Plan and Stemline Therapeutics, Inc. Amended and Restated 2004 Employee, Director and Consultant Stock Plan, and,
(2) Registration Statement (Form S-8 No. 333-206303) pertaining to Stemline Therapeutics, Inc. 2015 Employee Stock Purchase Plan,
(3) Registration Statement (Form S-8 No. 333-211784) pertaining to Stemline Therapeutics, Inc. 2016 Equity Incentive Plan;
of our report dated March 16, 2017, with respect to the financial statements of Stemline Therapeutics, Inc. included in this Annual Report (Form 10-K) of Stemline Therapeutics, Inc. for the year ended December 31, 2016.
/s/ Ernst & Young LLP |
|
|
|
Stamford, Connecticut |
|
March 16, 2017 |
|